Miller Howard Investments Inc. NY trimmed its position in shares of Pfizer (NYSE:PFE) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,170,182 shares of the biopharmaceutical company’s stock after selling 171,895 shares during the quarter. Pfizer makes up 1.7% of Miller Howard Investments Inc. NY’s portfolio, making the stock its 18th biggest holding. Miller Howard Investments Inc. NY’s holdings in Pfizer were worth $78,604,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Kanawha Capital Management LLC raised its holdings in shares of Pfizer by 1.2% in the fourth quarter. Kanawha Capital Management LLC now owns 182,909 shares of the biopharmaceutical company’s stock worth $6,625,000 after acquiring an additional 2,132 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its holdings in shares of Pfizer by 64.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 35,250 shares of the biopharmaceutical company’s stock worth $1,277,000 after acquiring an additional 13,800 shares during the last quarter. Eqis Capital Management Inc. raised its holdings in shares of Pfizer by 4.3% in the fourth quarter. Eqis Capital Management Inc. now owns 66,068 shares of the biopharmaceutical company’s stock worth $2,393,000 after acquiring an additional 2,719 shares during the last quarter. Foundry Partners LLC acquired a new position in shares of Pfizer in the fourth quarter worth $14,678,000. Finally, FTB Advisors Inc. raised its holdings in shares of Pfizer by 3.0% in the fourth quarter. FTB Advisors Inc. now owns 169,377 shares of the biopharmaceutical company’s stock worth $6,144,000 after acquiring an additional 4,888 shares during the last quarter. Institutional investors own 71.20% of the company’s stock.
A number of equities analysts have recently weighed in on PFE shares. SunTrust Banks reissued a “hold” rating and issued a $40.00 price target (up from $33.00) on shares of Pfizer in a report on Monday, January 29th. Jefferies Group set a $39.00 target price on Pfizer and gave the company a “hold” rating in a research note on Monday, February 26th. Morningstar set a $38.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a research note on Monday, January 15th. Finally, Bank of America set a $40.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $39.40.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm’s revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.47 earnings per share. research analysts predict that Pfizer will post 2.96 EPS for the current fiscal year.
Pfizer announced that its Board of Directors has approved a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
In other Pfizer news, insider Mikael Dolsten sold 13,986 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $35.85, for a total transaction of $501,398.10. Following the completion of the sale, the insider now directly owns 120,884 shares in the company, valued at $4,333,691.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the company’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total value of $1,515,973.68. The disclosure for this sale can be found here. Insiders have sold 248,037 shares of company stock valued at $9,064,785 over the last 90 days. 0.06% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This report was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.wkrb13.com/2018/04/02/pfizer-pfe-shares-sold-by-miller-howard-investments-inc-ny.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.